Urinary angiotensinogen is a marker for tubular injuries in patients with type 2 diabetes

International Journal of Nephrology and Renovascular Disease

Volumn 6, Issue , 2013, Pages 233-240

  Terami, Takahiro ^a   Wada, Jun ^a   Inoue, Kentaro ^a   Nakatsuka, Atsuko ^a   Ogawa, Daisuke ^a   Teshigawara, Sanae ^a   Murakami, Kazutoshi ^a   Katayama, Akihiro ^a   Eguchi, Jun ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

1 microglobulin; Albumin; Angiotensinogen; Diabetic nephropathy; Renin angiotensin system; Urinary biomarkers

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIDIABETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ADULT; ALBUMIN URINE LEVEL; ALPHA 1 MICROGLOBULIN URINE LEVEL; ANGIOTENSINOGEN URINE LEVEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINE LEVEL;

EID: 84886083504     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S51829     Document Type: Article

References (20)

1. Roksnoer LC, Verdonk K, van den Meiracker AH, Hoorn EJ, Zietse R, Danser AH. Urinary markers of intrarenal renin-angiotensin system activity in vivo. Curr Hypertens Rep. 2013;15(2):81-88.
2. Sawaguchi M, Araki SI, Kobori H, et al. Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus. J Diabetes Investig. 2012;3(3): 318-324.
3. Inoue K, Wada J, Eguchi J, et al. Urinary Fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray. PLoS ONE. In press.
4. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251-287.
5. van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, Danser AH. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int. 2001;60(6):2311-2317.
6. Kamiyama M, Zsombok A, Kobori H. Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes. J Pharmacol Sci. 2012;119(4):314-323.
7. Kobori H, Alper AB, Shenava R, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension. 2009;53(2):344-350.
8. Mills KT, Kobori H, Hamm LL, et al. Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrol Dial Transplant. 2012;27(8):3176-3181.
9. van den Heuvel M, Batenburg WW, Jainandunsing S, et al. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney. J Hypertens. 2011;29(11):2147-2155.
10. Hong CY, Hughes K, Chia KS, Ng V, Ling SL. Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care. 2003;26(2):338-342.
11. Korpinen E, Teppo AM, Hukkanen L, Akerblom HK, Grönhagen-Riska C, Vaarala O. Urinary transforming growth factor-beta1 and alpha1-microglobulin in children and adolescents with type 1 diabetes. Diabetes Care. 2000;23(5):664-668.
12. Pfleiderer S, Zimmerhackl LB, Kinne R, Manz F, Schuler G, Brandis M. Renal proximal and distal tubular function is attenuated in diabetes mellitus type 1 as determined by the renal excretion of alpha 1-microglobulin and Tamm-Horsfall protein. Clin Investig. 1993;71(12):972-977.
13. Petrica L, Petrica M, Vlad A, et al. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr. 2009;121(23-24):765-775.
14. Petrica L, Petrica M, Vlad A, et al. Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study. Nephron Clin Pract. 2011;118(2):c155-c164.
15. Richoux JP, Cordonnier JL, Bouhnik J, et al. Immunocytochemical localization of angiotensinogen in rat liver and kidney. Cell Tissue Res. 1983;233(2):439-451.
16. Saito T, Urushihara M, Kotani Y, Kagami S, Kobori H. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci. 2009;338(6):478-480.
17. Yamamoto T, Nakagawa T, Suzuki H, et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007;18(5):1558-1565.
18. Nishiyama A, Konishi Y, Ohashi N, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant. 2011;26(1):170-177.
19. Urushihara M, Kondo S, Kagami S, Kobori H. Urinary angiotensinogen accurately reflects intrarenal Renin-angiotensin system activity. Am J Nephrol. 2010;31(4):318-325.
20. Ogawa S, Kobori H, Ohashi N, et al. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights. 2009;4:97-102.